Sensorion Provides Update on Hearing Loss Gene Therapies
The company highlights progress in its SENS-501 and GJB2-GT clinical programs, recent financing, and a leadership transition.
The company highlights progress in its SENS-501 and GJB2-GT clinical programs, recent financing, and a leadership transition.
Updated pivotal trial results show that Regeneron’s investigational gene therapy DB-OTO led to rapid, clinically meaningful, and sustained hearing improvements in nearly all children with OTOF-related profound genetic hearing loss, with some achieving normal hearing and improved speech development.
Researchers have restored hearing in mice with ENPP1 deficiency using a novel bone-targeted enzyme replacement therapy, offering hope for treating hearing loss in patients with this rare and often fatal genetic disorder.
A new study reveals that binaural pitch fusion, crucial for understanding speech in noisy environments, continues to develop later than thought in children, presenting new opportunities for treatment and intervention.
In an article published on the ”Discover Magazine” website, author Sarah Katz challenges the view in the scientific community that deafness is a problem that needs to be cured, potentially by new CRISPR technology that could eliminate a TMC1 gene mutation.
Investigational gene therapy DB-OTO showed promising improvements in hearing and speech development in children with otoferlin-related genetic hearing loss.
Researchers have developed a novel vibration-based technique to more accurately diagnose balance disorders like Meniere’s disease, especially in aging adults.